Literature DB >> 28905192

SGLT2 inhibitors and cancer: why further evidence is required.

Altamash M Y Shaikh1,2,3.   

Abstract

Entities:  

Keywords:  Bladder; Canagliflozin; Cancer; Dapagliflozin; EMPA-REG; Empagliflozin; Gastrointestinal; Meta-analysis; SGLT1; SGLT2

Mesh：

Substances：

Year:  2017        PMID： 28905192     DOI： 10.1007/s00125-017-4434-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  5 in total

1.  Functional expression of sodium-glucose transporters in cancer.

Authors:  Claudio Scafoglio; Bruce A Hirayama; Vladimir Kepe; Jie Liu; Chiara Ghezzi; Nagichettiar Satyamurthy; Neda A Moatamed; Jiaoti Huang; Hermann Koepsell; Jorge R Barrio; Ernest M Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 3.  SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Huilin Tang; Qi Dai; Weilong Shi; Suodi Zhai; Yiqing Song; Jiali Han
Journal:  Diabetologia       Date:  2017-07-19       Impact factor: 10.122

Review 4.  A Review on the Relationship between SGLT2 Inhibitors and Cancer.

Authors:  Hao-Wen Lin; Chin-Hsiao Tseng
Journal:  Int J Endocrinol       Date:  2014-08-31       Impact factor: 3.257

5.  Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'.

Authors:  Agata Ptaszynska; Samuel M Cohen; Edward M Messing; Timothy P Reilly; Eva Johnsson; Kristina Johnsson
Journal:  Diabetes Ther       Date:  2015-09-01       Impact factor: 2.945
  5 in total
  4 in total

1.  Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter].

Authors:  Huilin Tang; Jiali Han; Yiqing Song
Journal:  Diabetologia       Date:  2017-09-17       Impact factor: 10.122

2.  Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.

Authors:  Bryce C Simes; Gordon G MacGregor
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-14       Impact factor: 3.168

Review 3.  The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms.

Authors:  Bing Zhu; Shen Qu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-11       Impact factor: 5.555

4.  SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Nanjing Shi; Yetan Shi; Jingsi Xu; Yuexiu Si; Tong Yang; Mengting Zhang; Derry Minyao Ng; Xiangyuan Li; Fei Xie
Journal:  Front Public Health       Date:  2021-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.